Immunovant, Inc.
IMVT
$15.08
$0.191.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 29.00% | 1.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.77% | -0.42% | |||
| Operating Income | -11.77% | 0.42% | |||
| Income Before Tax | -13.07% | 4.60% | |||
| Income Tax Expenses | 56.60% | 283.55% | |||
| Earnings from Continuing Operations | -13.31% | 4.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.31% | 4.21% | |||
| EBIT | -11.77% | 0.42% | |||
| EBITDA | -11.78% | 0.43% | |||
| EPS Basic | -10.57% | 15.59% | |||
| Normalized Basic EPS | -10.33% | 15.95% | |||
| EPS Diluted | -10.57% | 15.59% | |||
| Normalized Diluted EPS | -10.33% | 15.95% | |||
| Average Basic Shares Outstanding | 2.48% | 13.48% | |||
| Average Diluted Shares Outstanding | 2.48% | 13.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||